home / stock / polbf / polbf short
Short Information | Poolbeg Pharma plc Ord GBP 0.0002 (OTCMKTS:POLBF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 52,696 |
Total Actual Volume | 52,696 |
Short Trends | |
---|---|
Cover Days | 0 |
Short Days | 13 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 2,635 |
Average Short Percentage | 65.00% |
Is there a POLBF Short Squeeze or Breakout about to happen?
See the POLBF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
05-07-2024 | $0.2268 | $0.2269 | $0.2269 | $0.2268 | 3,384 | 3,384 | 100% |
05-01-2024 | $0.151 | $0.151 | $0.151 | $0.151 | 5,000 | 5,000 | 100% |
06-08-2023 | $0 | $0.115 | $0 | $0 | 2 | 2 | 100% |
02-07-2023 | $0.115 | $0.115 | $0.115 | $0.115 | 10,000 | 10,000 | 100% |
12-29-2022 | $0 | $0.073 | $0 | $0 | 7 | 7 | 100% |
12-02-2022 | $0.115 | $0.115 | $0.115 | $0.115 | 2,500 | 2,500 | 100% |
11-28-2022 | $0 | $0.121 | $0 | $0 | 1 | 1 | 100% |
11-22-2022 | $0.121 | $0.121 | $0.121 | $0.121 | 100 | 100 | 100% |
11-18-2022 | $0 | $0.121 | $0 | $0 | 1 | 1 | 100% |
11-17-2022 | $0.121 | $0.121 | $0.121 | $0.121 | 2,500 | 2,500 | 100% |
11-03-2022 | $0 | $0.079 | $0 | $0 | 1 | 1 | 100% |
11-02-2022 | $0.079 | $0.079 | $0.079 | $0.079 | 200 | 200 | 100% |
04-01-2022 | $0.1 | $0.1 | $0.1 | $0.0925 | 29,000 | 29,000 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Poolbeg Pharma plc Ord GBP 0.0002 Company Name:
POLBF Stock Symbol:
OTCMKTS Market:
(NewsDirect) Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) chief legal officer John McEvoy joins Proactive's Stephen Gunnion with news that POLB 001's Immuno-modulator II has received the fully granted patent from the US Patent Office. McEvoy explained the patent encompasses a class of d...
(NewsDirect) Poolbeg Pharma PLC CEO Jeremy Skillington and Tim Coté CEO of Silk Road Therapeutics join Proactive's Stephen Gunnion with details of an exclusive 12-month option agreement with Silk Road Therapeutics for Poolbeg to acquire a novel topical drug aimed at treating oral ulc...
Significant POLB 001 Patent Granted in United States Immunomodulator II patent grant further strengthens robust intellectual property portfolio for partnering LONDON, UK / ACCESSWIRE / May 1, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF, 'Poolbeg' or the 'Company'), a biopharm...